▎ 摘　　要

NOVELTY - Preparation of magnetic nanoparticle carrier involves ultrasonically dispersing magnetic graphene oxide powder in ethanol, stirring 3-aminopropyltrisethoxysilane, discarding supernatant, washing precipitates with ethanol and deionized water, freeze-drying, sonicating in deionized water, adding 1-ethyl(3-dimethylaminopropyl) carbodiimide hydrochloride and N-hydroxysuccinimide, agitating, adding aminated magnetic graphene nanocomposite to activated cyclodextrin-hyaluronic acid supramolecular polymer solution, stirring and freeze-drying. USE - Method for preparing magnetic nanoparticle carrier used for supporting doxurubicin hydrochloride (claimed). ADVANTAGE - The carrier solves technical problems of high toxicity and bad treatment effect. It has strong compatibility, low toxic and side effects with cancer cell target-locating effect, and controllable releasing characteristic. DETAILED DESCRIPTION - Preparation of magnetic nanoparticle carrier comprises: (A) preparing cyclodextrin-hyaluronic acid supramolecular polymer by adding 17-19 g beta -cyclodextrin and 11-12 g p-toluenesulfonyl chloride sequentially into 100-150 mL pyridine solvent, stirring for 5-8 hours at room temperature, removing pyridine solvent by rotary evaporation, purifying by recrystallization, washing with cold acetone to obtain precipitate mono-6-deoxy-6-(p-toluenesulfonyl)- beta -cyclodextrin; dissolving 4-6 g mono-6-deoxy-6-(p-toluenesulfonyl)- beta -cyclodextrin and 10-12 g ethylenediamine in 20-30 mL N,N-dimethylformamide, stirring magnetically at 80 degrees C for 18-24 hours under nitrogen protection, cooling mixture to room temperature, washing with 3-5 times cold acetone to remove residue of ethylenediamine and vacuum drying to obtain white powder; and activating 40-42 mg hyaluronic acid by 22-24 mg 1-ethyl (3-dimethylaminopropyl) carbodiimide hydrochloride and 13-15 mg N-hydroxysuccinimide solution, stirring for 2 hours to prepare dispersion, adding white powder to dispersion, allowing mixture to react for 18-24 hours at room temperature, dialyzing with deionized water, and freeze-drying to obtain cyclodextrin-hyaluronic acid supermolecule polymer; (B) preparing magnetic graphene oxide by dissolving 180-220 mg graphene oxide in deionized water for 1 hour by sonication to prepare graphene oxide dispersion, placing in three-necked flask, heating to 60-80 degrees C, bubbling nitrogen gas in graphene oxide solution for 10-15 minutes to remove air, mechanically stirring at 800 revolutions/minute in nitrogen atmosphere, dissolving 2.7 g ferric chloride hexahydrate and 1.0 g ferrous chloride tetrahydrate in graphene oxide solution to prepare reaction solution, and adding concentrated ammonia solution dropwise until pH of reaction solution is adjusted to 9-12; stirring at 80 degrees C for 1-3 hours to get magnetic black precipitate; cooling to room temperature, carrying out hysteresis separation, washing black precipitates repeatedly with deionized water and anhydrous ethanol, and freeze-drying for 20-30 hours to obtain magnetic graphene oxide powder; and (C) preparing cyclodextrin-hyaluronan polymer functionalized magnetic nanocarrier by ultrasonically dispersing 180-220 mg magnetic graphene oxide powder in 180-220 mL ethanol for 30-40 minutes to ensure complete dissolution under nitrogen atmosphere, stirring 200-400 mu L 3-aminopropyltrisethoxysilane, and mechanical stirring at room temperature for 6-8 hours; discarding supernatant by hysteresis separation, washing precipitates with ethanol and deionized water for greater than or equal to 3 times, and freeze-drying to obtain amination magnetic graphene oxide nanocomposite; sonicating 48-52 mg cyclodextrin-hyaluronic acid supramolecular polymer in deionized water for 1-3 hours, adding 22-24 mg 1-ethyl(3-dimethylaminopropyl) carbodiimide hydrochloride and 13-15 mg N-hydroxysuccinimide, agitating continuously for 2-4 hours to activate carboxyl groups of cyclodextrin-hyaluronic acid supramolecular polymer; and adding aminated magnetic graphene nanocomposite to activated cyclodextrin-hyaluronic acid supramolecular polymer solution, stirring at room temperature for 24-48 hours and freeze-drying to obtain cyclodextrin-hyaluronic acid polymer functionalized magnetic nanoparticle carrier. An INDEPENDENT CLAIM is included for supporting doxorubicin hydrochloride using magnetic nanodrug carrier comprising adding 4 mL 1-300 mg/L doxorubicin hydrochloride solution with 0.5 mg cyclodextrin-hyaluronic acid polymer functionalized magnetic nanodrug carrier, shaking at room temperature for 7 hours, and separating.